Oncolytics Accelerates Enrollment in REO 033 Colorectal Cancer Study
Nearly all planned clinical sites for the REO 033 study are activated, and multiple patients are currently enrolled. The company expects to provide an interim clinical update by year-end based on objective response rate data.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed